泊马度胺不良反应文献分析  

Literature analysis of adverse drug reactions induced by pomalidomide

作　　者：刘梦颖[1] 姚瑶[1] 徐喜慧[2] LIU Meng-ying;YAO Yao;XU Xi-hui(Department of Pharmacy,Nanjing Drum Tower Hospital,Affiliated Hospital of Nanjing University,Jiangsu Nanjing 210008,China;Department of Hematology,Nanjing Drum Tower Hospital,Affiliated Hospital of Nanjing University,Jiangsu Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院药学部,江苏南京210008 [2]南京大学医学院附属鼓楼医院血液科,江苏南京210008

出　　处：《中国医院药学杂志》2022年第17期1817-1820,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨泊马度胺所致药物不良反应(adverse drug reaction,ADR)的发生情况和临床特征,为临床安全合理用药提供参考。方法:检索中国知网、万方、维普、PubMed、Embase、Web of Science数据库收载的ADR个案,进行统计分析。结果:收集泊马度胺致ADR的个案报道21篇共23例,其中男性12例(52.17%),女性11例(47.83%),年龄分布以60岁以上居多(18例,78.26%);原患疾病主要为多发性骨髓瘤(21例,91.30%);ADR多发生在用药后270 d内(19例,82.61%),主要累及呼吸系统(7例,30.43%)和中枢神经系统(6例,26.09%),其中肺损伤、进行性多灶性白质脑病、甲状腺功能减退、急性肾损伤等为药品说明书未记载的ADR。结论:临床应加强对泊马度胺相关ADR的认识和监测,及时诊断与治疗,确保用药安全。OBJECTIVE To investigate the occurrence and clinical characteristics of adverse drug reactions(ADR)induced by pomalidomide and provide reference for the clinical medication.METHODS Case reports on the ADRs induced by pomalidomide were retrieved from the databases of CNKI,WanFang,VIP,PubMed,Embase and Web of Science.RESULTS A total of 23 cases were reported in 21 papers,including 12 males(52.17%)and 11 females(47.83%).Patients aged over 60 years showed the highest percentage(n=18,78.26%)and the primary disease was multiple myeloma(n=21,91.30%).ADR induced by pomalidomide mostly occurred within 270 d after medication(n=19,82.61%),mainly involving respiratory system(n=7,30.43%)and central nervous system(n=6,26.09%);lung injury,progressive multifocal leukoencephalopathy,hypothyroidism and acute kidney injury belonged to the ADRs not recorded in the drug instruction.CONCLUSION Clinicians and pharmacists should strengthen the understanding and monitoring of ADR induced by pomalidomide,timely perform diagnosis and treatment in order to ensure the safe use of pomalidomide.

关 键 词：泊马度胺 药物不良反应 免疫调节剂 文献分析 

分 类 号：R979.1[医药卫生—药品]